IMVARIA
About IMVARIA
IMVARIA is a pioneering health tech company based in Berkeley, CA, specializing in AI-driven digital biomarker solutions. Founded in 2019 by physician-engineers from Google and Stanford University, IMVARIA aims to empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease, reducing the need for invasive biopsy testing.
IMVARIA operates its AI Lab, a centralized, cloud-based digital lab that uses automated machine-learning algorithms to transform clinical decision-making into data science. The company's platform integrates imaging modalities, including CT and MRI, and lab data following international quality standards (e.g., ISO 13485).
The company has developed FDA-authorized digital biomarker tools such as Fibresolve, the first FDA-authorized AI biomarker solution for non-invasive diagnosis of lung fibrosis, and ScreenDx, an AI-powered screening algorithm for interstitial lung disease (ILD). These tools assist pulmonologists and clinicians in diagnosing and managing complex lung diseases including idiopathic pulmonary fibrosis (IPF) and ILD.
IMVARIA collaborates with leading medical institutions such as Mayo Clinic to advance AI biomarkers for cancer and other diseases. The company is dedicated to advancing healthcare through AI innovation and is expanding its geographic presence via strategic partnerships.
IMVARIA is a remote-first company actively growing its engineering and commercial teams, encouraging flexible work schedules and digital collaboration.
IMVARIA operates its AI Lab, a centralized, cloud-based digital lab that uses automated machine-learning algorithms to transform clinical decision-making into data science. The company's platform integrates imaging modalities, including CT and MRI, and lab data following international quality standards (e.g., ISO 13485).
The company has developed FDA-authorized digital biomarker tools such as Fibresolve, the first FDA-authorized AI biomarker solution for non-invasive diagnosis of lung fibrosis, and ScreenDx, an AI-powered screening algorithm for interstitial lung disease (ILD). These tools assist pulmonologists and clinicians in diagnosing and managing complex lung diseases including idiopathic pulmonary fibrosis (IPF) and ILD.
IMVARIA collaborates with leading medical institutions such as Mayo Clinic to advance AI biomarkers for cancer and other diseases. The company is dedicated to advancing healthcare through AI innovation and is expanding its geographic presence via strategic partnerships.
IMVARIA is a remote-first company actively growing its engineering and commercial teams, encouraging flexible work schedules and digital collaboration.
Mission and Technology
IMVARIA's mission is to advance non-invasive AI biomarkers to improve patient lives by redefining clinical assessments in serious diseases. Their AI biomarkers leverage high-quality clinical imaging and laboratory data to provide unique insights into diagnosis and disease assessment.
IMVARIA's SaMD (software-as-medical-device) tools are transforming clinical decision-making and therapeutic development by delivering precise AI-driven digital biomarker technology.
The company serves clinicians, health systems, and life sciences sectors, optimizing study enrollment, patient risk stratification, and treatment response predictions in clinical trials.
For more information, visit www.imvaria.com.
IMVARIA's SaMD (software-as-medical-device) tools are transforming clinical decision-making and therapeutic development by delivering precise AI-driven digital biomarker technology.
The company serves clinicians, health systems, and life sciences sectors, optimizing study enrollment, patient risk stratification, and treatment response predictions in clinical trials.
For more information, visit www.imvaria.com.